Literature DB >> 16338657

Revealing the genomic heterogeneity of melanoma.

Omar Kabbarah1, Lynda Chin.   

Abstract

The melanoma genome possesses numerous recurrent chromosomal rearrangements, and embedded within this complexity are clues critical to disease pathogenesis and response to therapy. High-resolution genome-wide DNA copy number approaches, in conjunction with gene-specific mutational analyses, appear poised to define keystone molecular events, provide more accurate classification schemes, and set the stage for the design of rational therapies that may finally have an impact on survival of this deadly disease.

Entities:  

Mesh:

Year:  2005        PMID: 16338657     DOI: 10.1016/j.ccr.2005.11.008

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  14 in total

Review 1.  Molecular biology of malignant melanoma and other cutaneous tumors.

Authors:  M Pons; M Quintanilla
Journal:  Clin Transl Oncol       Date:  2006-07       Impact factor: 3.405

2.  A novel role for microphthalmia-associated transcription factor-regulated pigment epithelium-derived factor during melanoma progression.

Authors:  Soheil S Dadras; Richard J Lin; Gita Razavi; Akinori Kawakami; Jinyan Du; Erez Feige; Daniel A Milner; Massimo F Loda; Scott R Granter; Michael Detmar; Hans R Widlund; Martin A Horstmann; David E Fisher
Journal:  Am J Pathol       Date:  2014-11-06       Impact factor: 4.307

3.  Characterization of nonacral melanoma patients without typical risk factors.

Authors:  Maria M Canelas; Justo Lorenzo Bermejo; Maria Teresa Landi; Celia Requena; Carlos Guillen; Rajiv Kumar; Eduardo Nagore
Journal:  Melanoma Res       Date:  2012-08       Impact factor: 3.599

4.  Bortezomib pre-treatment prolongs interferon-alpha-induced STAT1 phosphorylation in melanoma cells.

Authors:  Gregory B Lesinski; Kristen Benninger; Melanie Kreiner; Megan Quimper; Gregory Young; William E Carson
Journal:  Cancer Immunol Immunother       Date:  2009-04-26       Impact factor: 6.968

5.  Mutational load distribution analysis yields metrics reflecting genetic instability during pancreatic carcinogenesis.

Authors:  Gemma Tarafa; David Tuck; Daniela Ladner; Mark Topazian; Randall Brand; Carolyn Deters; Victor Moreno; Gabriel Capella; Henry Lynch; Paul Lizardi; Jose Costa
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-12       Impact factor: 11.205

6.  Distinct patterns of DNA copy number alterations associate with BRAF mutations in melanomas and melanoma-derived cell lines.

Authors:  J Greshock; K Nathanson; A Medina; M R Ward; M Herlyn; B L Weber; T Z Zaks
Journal:  Genes Chromosomes Cancer       Date:  2009-05       Impact factor: 5.006

7.  Differential Expression of BARD1 Isoforms in Melanoma.

Authors:  Lorissa I McDougall; Ryan M Powell; Magdalena Ratajska; Chi F Lynch-Sutherland; Sultana Mehbuba Hossain; George A R Wiggins; Agnieszka Harazin-Lechowska; Bożena Cybulska-Stopa; Jyoti Motwani; Erin C Macaulay; Glen Reid; Logan C Walker; Janusz Ryś; Michael R Eccles
Journal:  Genes (Basel)       Date:  2021-02-23       Impact factor: 4.096

8.  c-Abl and Arg are activated in human primary melanomas, promote melanoma cell invasion via distinct pathways, and drive metastatic progression.

Authors:  S S Ganguly; L S Fiore; J T Sims; J W Friend; D Srinivasan; M A Thacker; M L Cibull; C Wang; M Novak; D M Kaetzel; R Plattner
Journal:  Oncogene       Date:  2011-09-05       Impact factor: 9.867

9.  Aggressiveness of human melanoma xenograft models is promoted by aneuploidy-driven gene expression deregulation.

Authors:  Véronique Mathieu; Christine Pirker; Wolfgang M Schmidt; Sabine Spiegl-Kreinecker; Daniela Lötsch; Petra Heffeter; Balazs Hegedus; Michael Grusch; Robert Kiss; Walter Berger
Journal:  Oncotarget       Date:  2012-04

10.  Database of Trypanosoma cruzi repeated genes: 20,000 additional gene variants.

Authors:  Erik Arner; Ellen Kindlund; Daniel Nilsson; Fatima Farzana; Marcela Ferella; Martti T Tammi; Björn Andersson
Journal:  BMC Genomics       Date:  2007-10-26       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.